Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Everest Medicines Limited, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia, announced today that the Taiwan FDA had accepted the su ...
FDA Grants Priority Review for OPNT003 Nasal Nalmefene to Treat Opioid Overdose
The FDA has accepted for Priority Review the New Drug Application for Opiant Pharmaceutical's OPNT003, an intranasal formulation containing the high-affinity opioid antagonist nalmefene, for the treat ...
Legend Biotech Announces Acceptance of Ciltacabtagene Autoleucel (Cilta-Cel) NDA in China
Legend Biotech Corp. announced that China's National Medical Products Administration accepted its New Drug Application for ciltacabtagene autoleucel, a novel therapy to treat life-threatening diseases ...